Related Experiment Videos
The management of ventricular arrhythmias in older patients after CAST
1Hebrew Hospital Home, New York, New York.
Insights
Elderly individuals with asymptomatic ventricular arrhythmias without heart disease should avoid antiarrhythmic drugs. Treatment for those with heart disease focuses on beta-blockers, ACE inhibitors, and potentially implantable cardioverter-defibrillators for severe cases.
Area of Science:
- Cardiology
- Geriatric Medicine
- Electrophysiology
Background:
- Nonsustained ventricular tachycardia and complex ventricular arrhythmias in the elderly are linked to increased risks of coronary events, ventricular fibrillation, and sudden cardiac death.
- Risk factors include abnormal left ventricular ejection fraction, left ventricular hypertrophy, and silent ischemia.
- Management strategies are crucial for this demographic.
Purpose of the Study:
- To outline evidence-based treatment guidelines for ventricular arrhythmias in elderly patients.
- To differentiate management approaches based on the presence or absence of underlying heart disease.
- To provide recommendations for drug therapy and invasive interventions.
Main Methods:
- Review of current literature and clinical guidelines on ventricular arrhythmias in the elderly.
- Analysis of risk factors and prognostic indicators associated with ventricular arrhythmias.
- Formulation of treatment algorithms based on patient characteristics and arrhythmia severity.
Main Results:
- Asymptomatic ventricular arrhythmias without heart disease in the elderly do not warrant antiarrhythmic drug treatment.
- Beta-blockers are recommended for ventricular arrhythmias associated with ischemic or non-ischemic heart disease.
- ACE inhibitors are indicated for arrhythmias with congestive heart failure; combination therapy with beta-blockers is suggested for systolic dysfunction.
- Amiodarone is reserved for life-threatening arrhythmias unresponsive to beta-blockers.
- Invasive interventions, including automatic implantable cardioverter-defibrillators, are recommended for medically refractory sustained ventricular tachyarrhythmias or ventricular fibrillation.
Conclusions:
- Treatment decisions for ventricular arrhythmias in the elderly must be individualized.
- Antiarrhythmic drugs should be used cautiously, with a focus on underlying conditions and arrhythmia severity.
- Beta-blockers and ACE inhibitors form the cornerstone of pharmacologic management.
- Implantable cardioverter-defibrillators are crucial for high-risk patients with refractory arrhythmias.
Abstract:
Asymptomatic nonsustained ventricular tachycardia and complex ventricular arrhythmias in elderly persons without heart disease should not be treated with antiarrhythmic drugs. Nonsustained ventricular tachycardia and complex ventricular arrhythmias in elderly persons are associated with an increased incidence of coronary events, primary ventricular fibrillation and sudden cardiac death, especially if abnormal left ventricular ejection fraction, left ventricular hypertrophy or silent ischaemia are present. beta-Blockers should be used in the treatment of elderly patients with ventricular tachycardia or complex ventricular arrhythmias associated with ischaemic or nonischaemic heart disease if there are no contraindications to beta-blocker therapy. I would reserve the use of amiodarone in the treatment of ventricular tachycardia or complex ventricular arrhythmias to life-threatening ventricular tachyarrhythmias in elderly patients who cannot tolerate or who do not respond to beta-blockers. Angiotensin converting enzyme (ACE) inhibitors should be used in treating elderly patients with ventricular tachycardia or complex ventricular arrhythmias associated with congestive heart failure. In patients with ventricular tachycardia or complex ventricular arrhythmias associated with asymptomatic left ventricular systolic dysfunction, I would use beta-blockers plus ACE inhibitors. If elderly patients have life-threatening, recurrent ventricular tachycardia or ventricular fibrillation resistant to antiarrhythmic drugs, invasive intervention is indicated. Until the results of prospective, randomised, clinical trials evaluating the automatic implantable cardioverter-defibrillator are available, I recommend using the automatic implantable cardioverter-defibrillator in elderly patients who have medically refractory sustained ventricular tachycardia or ventricular fibrillation.